Payment overview · 2025
General Payments
$890.15
62 reported records · 12 companies
Healthcare provider profile · identity verified
Christopher M Basham, MD
Allopathic & Osteopathic Physicians|Family Medicine · NORTON, VA · NPI 1831160530
Verified facts
What the public records show
CMS Open Payments records show Christopher M Basham, MD received $890.15 in general payments during 2025 across 62 reported records.
Novo Nordisk Inc accounted for 32.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Jardiance, Linzess, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 313 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 327 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 313 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $287.48 | 32.3% | 19 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $216.62 | 24.3% | 20 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $88.04 | 9.9% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $73.33 | 8.2% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $37.33 | 4.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.91 | 4.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.41 | 3.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $31.96 | 3.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.54 | 3.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.29 | 2.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.51 | 2.3% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.73 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $890.15 | 62 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $130.88 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $130.88 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $123.74 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $95.46 | 8 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $88.04 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $73.33 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $62.23 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $39.55 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $37.33 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $35.91 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.41 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $34.41 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $31.96 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $30.65 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $30.65 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.51 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 313 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 172 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 82 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 111 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 57 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
82 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
65 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
313 | 64 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
172 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
327 | 60 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
111 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
57 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
313 | 64 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
35 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1014 | 210 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 788 | 197 |
| Amlodipine Besylate | Amlodipine Besylate | 742 | 182 |
| Atorvastatin Calcium | Atorvastatin Calcium | 668 | 162 |
| Losartan Potassium | Losartan Potassium | 666 | 157 |
| Gabapentin | Gabapentin | 615 | 102 |
| Omeprazole | Omeprazole | 587 | 145 |
| Metoprolol Succinate | Metoprolol Succinate | 574 | 121 |
| Metformin Hcl | Metformin Hcl | 474 | 129 |
| Duloxetine Hcl | Duloxetine Hcl | 370 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 347 | 81 |
| Metoprolol Tartrate | Metoprolol Tartrate | 343 | 82 |
| Lisinopril | Lisinopril | 341 | 89 |
| Trazodone Hcl | Trazodone Hcl | 334 | 80 |
| Mounjaro | Tirzepatide | 327 | 60 |
| Montelukast Sodium | Montelukast Sodium | 326 | 75 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 317 | 73 |
| Eliquis | Apixaban | 313 | 64 |
| Furosemide | Furosemide | 281 | 62 |
| Meloxicam | Meloxicam | 258 | 63 |
| Tizanidine Hcl | Tizanidine Hcl | 253 | 54 |
| Ezetimibe | Ezetimibe | 251 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 250 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 234 | 89 |
| Potassium Chloride | Potassium Chloride | 222 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 213 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 201 | 50 |
| Ondansetron Odt | Ondansetron | 196 | 57 |
| Allopurinol | Allopurinol | 190 | 52 |
| Clonazepam | Clonazepam | 190 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 189 | 50 |
| Famotidine | Famotidine | 188 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 182 | 46 |
| Pregabalin | Pregabalin | 179 | 35 |
| Jardiance | Empagliflozin | 172 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 170 | 48 |
| Simvastatin | Simvastatin | 170 | 46 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 163 | 40 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 163 | 29 |
| Carvedilol | Carvedilol | 156 | 38 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 144 | 32 |
| Warfarin Sodium | Warfarin Sodium | 139 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 136 | 37 |
| Lorazepam | Lorazepam | 134 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 132 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 131 | 23 |
| Sertraline Hcl | Sertraline Hcl | 126 | 23 |
| Spironolactone | Spironolactone | 124 | 34 |
| Doxycycline Hyclate | Doxycycline Hyclate | 123 | 94 |
| Torsemide | Torsemide | 123 | 29 |
| Metformin Hcl Er | Metformin Hcl | 120 | 28 |
| Ibuprofen | Ibuprofen | 119 | 29 |
| Mirtazapine | Mirtazapine | 119 | 25 |
| Ozempic | Semaglutide | 111 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 106 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 105 | 26 |
| Celecoxib | Celecoxib | 101 | 24 |
| Azithromycin | Azithromycin | 100 | 79 |
| Glimepiride | Glimepiride | 99 | 25 |
| Tramadol Hcl | Tramadol Hcl | 98 | 22 |
| Baclofen | Baclofen | 96 | 21 |
| Methylprednisolone | Methylprednisolone | 96 | 64 |
| Alprazolam | Alprazolam | 90 | 14 |
| Sucralfate | Sucralfate | 90 | 21 |
| Cephalexin | Cephalexin | 89 | 52 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 88 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 88 | 16 |
| Methocarbamol | Methocarbamol | 87 | 18 |
| Cefdinir | Cefdinir | 86 | 73 |
| Atenolol | Atenolol | 84 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 84 | 26 |
| Finasteride | Finasteride | 83 | 20 |
| Topiramate | Topiramate | 83 | 22 |
| Linzess | Linaclotide | 82 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 81 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 80 | 18 |
| Lansoprazole | Lansoprazole | 78 | 20 |
| Lactulose | Lactulose | 71 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 15 |
| Synthroid | Levothyroxine Sodium | 65 | 19 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 64 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | 11 |
| Nystatin | Nystatin | 63 | 32 |
| Bupropion Xl | Bupropion Hcl | 62 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 61 | 12 |
| Divalproex Sodium | Divalproex Sodium | 61 | 11 |
| Nateglinide | Nateglinide | 57 | 12 |
| Rybelsus | Semaglutide | 57 | 15 |
| Januvia | Sitagliptin Phosphate | 56 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 55 | 15 |
| Telmisartan | Telmisartan | 55 | 13 |
| Fluconazole | Fluconazole | 54 | 36 |
| Meclizine Hcl | Meclizine Hcl | 53 | 15 |
| Farxiga | Dapagliflozin Propanediol | 51 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 50 | 39 |
| Clonidine Hcl | Clonidine Hcl | 49 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 49 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 48 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 36 |
| Ondansetron Hcl | Ondansetron Hcl | 47 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 17 |
| Buspirone Hcl | Buspirone Hcl | 46 | 11 |
| Donepezil Hcl | Donepezil Hcl | 46 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | suppressed |
| Naproxen | Naproxen | 41 | 15 |
| Prednisone | Prednisone | 41 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | 12 |
| Benazepril Hcl | Benazepril Hcl | 40 | 12 |
| Carbamazepine | Carbamazepine | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | 13 |
| Lamotrigine | Lamotrigine | 39 | 12 |
| Nitroglycerin | Nitroglycerin | 39 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 39 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 37 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 11 |
| Eplerenone | Eplerenone | 38 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 38 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 36 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 36 | suppressed |
| Estradiol | Estradiol | 35 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 35 | 34 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 34 | 11 |
| Levofloxacin | Levofloxacin | 33 | 24 |
| Metronidazole | Metronidazole | 33 | 19 |
| Mupirocin | Mupirocin | 30 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 20 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Dutasteride | Dutasteride | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Testosterone | Testosterone | 25 | suppressed |
| Ibu | Ibuprofen | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 22 | suppressed |
| Fentanyl | Fentanyl | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Scopolamine | Scopolamine | 21 | 12 |
| Amoxicillin | Amoxicillin | 20 | 18 |
| Carbamazepine Er | Carbamazepine | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Humulin R | Insulin Regular, Human | 19 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Oxazepam | Oxazepam | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Roflumilast | Roflumilast | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 16 | 14 |
| Methylphenidate Hcl | Methylphenidate Hcl | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Ursodiol | Ursodiol | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | 11 |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Alprazolam Xr | Alprazolam | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Multaq | Dronedarone Hcl | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $890.15 · 62 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, CAPLYTA, CREON, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, JARDIANCE, LEQVIO, LINZESS, NEXLETOL, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Wegovy, ZAVZPRET | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error